<DOC>
	<DOC>NCT02350569</DOC>
	<brief_summary>This study will evaluate the safety, tolerability, antiviral efficacy, and pharmacokinetics of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) administered for 4 weeks in adults with genotype 1 or 4 hepatitis C virus (HCV) infection who are undergoing primary liver transplantation.</brief_summary>
	<brief_title>Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic Genotype 1 or 4 HCV for Use in the Peri-Operative Liver Transplantation Setting</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<mesh_term>Ledipasvir, sofosbuvir drug combination</mesh_term>
	<criteria>Willing and able to provide written informed consent or for those individuals where hepatic encephalopathy affects their ability to provide initial or ongoing consent, has an appropriate and legallyauthorized representative (LAR) willing and able to provide consent on behalf of the individual. HCV RNA infection with quantifiable virus at screening Must have chronic genotype 1 or 4 HCV infection Currently on the liver transplantation wait list Screening electrocardiogram (ECG) without clinically significant abnormalities. A negative serum pregnancy test result is required for females Any previous solid organ transplant Any serious or active medical or psychiatric illness which, in the opinion of the investigator, would interfere with treatment, assessment, or compliance HIV infection or a positive hepatitis B virus surface antigen result History of malignancy Treatment with any approved or experimental medication with known antiHCV activity within 1 month prior to screening date Prior exposure to an HCV nonstructural protein (NS)5A inhibitor Patients on hemodialysis prior to or at the time of transplantation will be excluded Creatinine clearance (CLcr) &lt; 40 mL/min at screening or &lt; 40 mL/min on day of transplant Participation in a clinical study with an investigational drug or biologic within 28 days prior to screening visit Receipt or planned receipt of an organ from an HCV positive donor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>liver transplant</keyword>
	<keyword>hepatitis C</keyword>
	<keyword>Gilead</keyword>
	<keyword>Communicable Diseases</keyword>
	<keyword>Infection</keyword>
	<keyword>Virus Diseases</keyword>
	<keyword>Digestive System Diseases</keyword>
	<keyword>Hepatitis</keyword>
	<keyword>Hepatitis, Viral, Human</keyword>
	<keyword>Liver Diseases</keyword>
	<keyword>RNA Virus Infections</keyword>
</DOC>